Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 353-360

  Wozniak, A ^a,b   Rutkowski, P ^c   Piskorz, A ^a   Ciwoniuk, M ^a   Osuch, C ^d   Bylina, E ^c   Sygut, J ^e   Chosia, M ^f   Rys, J ^g   Urbanczyk, K ^d   Kruszewski, W ^a,h   Sowa, P ⁱ   Siedlecki, J ^c   Debiec rychter, M ^j   Limon, J ^a   Biernat, W ^k   Izycka Swieszewska, E ^k   Kakol, M ^k   Matlok, M ^k   Michej, W ^k  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Katholieke Universiteit   (Belgium)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e Swietokrzyskie Centrum Onkologii Poland   (Poland)

^f POMERANIAN MEDICAL UNIVERSITY   (Poland)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h PCK's Maritime Hospital in Gdynia   (Poland)

ⁱ Department of Pathology   (Poland)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k NONE

more..

Author keywords

GIST; Imatinib; KIT; Mutations; PDGFRA; Prognosis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; CHILD; CLINICAL FEATURE; CODON; CONTROLLED STUDY; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIT GENE; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA GENE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; SCHOOL CHILD; STOMACH TUMOR; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; YOUNG ADULT;

EID: 84856354552     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr127     Document Type: Article

References (32)

1. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumours that is more specific than CD34. Mod Pathol 1998; 11: 728-734.
2. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. Science 1998; 279: 577-580.
3. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumours. Science 2003; 299: 708-710.
4. Wozniak A, Floris G, Debiec-Rychter M et al. Implications of mutational analysis for the management of patients with gastrointestinal stromal tumours and the application of targeted therapies. Cancer Invest 2010; 28: 839-848.
5. Corless CL, McGreevey L, Haley A et al. KIT mutations are common in incidental gastrointestinal stromal tumours one centimeter or less in size. Am J Pathol 2002; 160: 1567-1572.
6. Agaimy A, Wü nsch PH, Dirnhofer S et al. Microscopic gastrointestinal stromal tumours in esophageal and intestinal surgical resection specimens: a clinicopathologic, immunohistochemical, and molecular study of 19 lesions. Am J Surg Pathol 2008; 32: 867-873.
7. Miettinen M, Lasota J. Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-1478.
8. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008; 53: 245-266.
9. Wardelmann E, Losen I, Hans V et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumours. Int J Cancer 2003; 106: 887-895.
10. Martín J, Poveda A, Llombart-Bosch A et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumours: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005; 23: 6190-6198.
11. Antonescu CR, Sommer G, Sarran L et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumours. Clin Cancer Res 2003; 9: 3329-3337.
12. Lasota J, Kopczynski J, Sarlomo-Rikala M et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumours of intestinal origin. Hum Pathol 2003; 34: 1306-1312.
13. Lasota J, vel Dobosz AJ, Wasag B et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumours. Lab Invest 2007; 87: 1029-1041.
14. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumours of low or no malignant potential. Lab Invest 2004; 84: 874-883.
15. Corless CL, Schroeder A, Griffith D et al. PDGFRA mutations in gastrointestinal stromal tumours: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-5364.
16. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103.
17. Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumour: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-5367.
18. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Soft tissue sarcoma V.2.2009. 2009; http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf.
19. Rutkowski P, Nowecki ZI, Michej W et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumour. Ann Surg Oncol 2007; 14: 2018-2027.
20. Ruka W, Rutkowski P, Kulig J et al. Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2008. Nowotwory J Oncol 2008; 58: 537-549.
21. Ruka W, Rutkowski P, Nowecki ZI et al. Other malignant neoplasms in patients with gastrointestinal stromal tumors (GIST). Med Sci Monit 2004; 18: LE13-LE14.
22. Emile JF, Brahimi S, Coindre J et al. Molecular epidemiology of GISTs: incidence of PDGFRA and KIT exon 9 mutations in the large French population-based study molecGIST. J Clin Oncol 2009; 15s (suppl): Abstr 10535.
23. Emile J, Brahimi S, Coindre J et al. Prognostic value of the most frequent mutations in GIST: results of the French population-based prospective study MolecGIST. J Clin Oncol 2010; 15s (suppl) (Abstr 10034).
24. Steigen SE, Eide TJ, Wasag B et al. Mutations in gastrointestinal stromal tumours-a population-based study from Northern Norway. APMIS 2007; 115: 289-298.
25. Tryggvason G, Hilmarsdottir B, Gunnarsson GH et al. Tyrosine kinase mutations in gastrointestinal stromal tumours in a nation-wide study in Iceland. APMIS 2010; 118: 648-656.
26. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumours of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68.
27. Andersson J, Bümming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumours with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 2006; 130: 1573-1581.
28. Martin-Broto J, Gutierrez A, Garcia-del-Muro X et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapsee-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 2010; 21: 1552-1557.
29. Singer S, Rubin BP, Lux ML et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumours. J Clin Oncol 2002; 20: 3898-3905.
30. Lasota J, Dansonka-Mieszkowska A, Stachura T et al. Gastrointestinal stromal tumours with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 2003; 16: 1257-1264.
31. Corless CL, McGreevey L, Town A et al. KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumours. J Mol Diagn 2004; 6: 366-370.
32. Lasota J, Corless CL, Heinrich MC et al. Clinicopathologic profile of gastrointestinal stromal tumours (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 2008; 21: 476-484.